Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02356588 · ClinicalTrials.gov registry record · Phase 3
A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery
A Phase 3 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 3
- Development phase
- 161
- Enrollment target
NCT02356588 is a Phase 3 study that has completed, run by Talphera. The registered enrollment target is 161 participants.
The verdict
NCT02356588, a Phase 3 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 161 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.
Interventions
- DRUG Placebo Tablet
- DRUG Sufentanil Tablet 30 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2015-02 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02356588
The ClinicalTrials.gov registry entry for NCT02356588 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablet is the first listed.
NCT02356588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02356588 about?
NCT02356588 is a clinical study titled "A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery". The purpose of this study is to compare the efficacy and safety of the sublingual Sufentanil Tablet (ST) 30 mcg to the sublingual Placebo Tablet (PT) for the short-term management of moderate-to-severe acute post-operative pain in patients after abdominal surgery.
What is the current status of trial NCT02356588?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2015-02. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02356588?
The interventions under investigation include: Placebo Tablet (DRUG), Sufentanil Tablet 30 mcg (DRUG).
Who is sponsoring clinical trial NCT02356588?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.